Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients

Expert Opinion on Drug Safety

Volumn 7, Issue 4, 2008, Pages 389-400

  Harris, Marianne ^a  

^a NONE   (Canada)

Author keywords

Acute interstitial nephritis; Antiretroviral therapy; Drug drug interacuons; Highly active antiretroviral therapy; HIV; Indinavir; Kidney disease; Membranoproliferative glomerulonephritis; Nephrotoxicity; Obstructive nephropathy; Renal tubular disorders; Tenofovir

Indexed keywords

ABACAVIR; ADEFOVIR; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; CIDOFOVIR; COTRIMOXAZOLE; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; FOSCARNET; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAMIDINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG;

ACIDOSIS; ACUTE KIDNEY FAILURE; CREATININE BLOOD LEVEL; CRYSTALLURIA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FIBROSING ALVEOLITIS; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE DISORDER; KIDNEY TUBULE NECROSIS; LEUKOCYTURIA; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MITOCHONDRIAL TOXICITY; MYOGLOBINURIA; NEPHROGENIC DIABETES INSIPIDUS; NEPHROLITHIASIS; NEPHROTOXICITY; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; VIRUS LOAD;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 48749125720     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.4.389     Document Type: Review

References (152)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4
3. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007;21(6):685-92
4. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96
5. Szczech LA, Gange SJ, Van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002;61:195-202
6. Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007;21:2101-3
7. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006;20:561-5
8. Izzedine H, Deray G. Nephrology in the HAART era. AIDS 2007;21(4):409-21
9. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-85
10. Mazber SA, Schoenfeld PY, Humphreys MH. Renal involvement in patients infected with HIV: experience at San Francisco General Hospital. Kidney Int 1990;37:1325-32
11. Winston JA, Klotman ME, Klotman PE. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 1999;55:1036-40
12. Cohen AH, Sun NC, Shapshak PO, Imagawa DT. Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod Pathol 1989;2:125-8
13. Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000;11:2079-87
14. Marras D, Bruggeman LA, Gao F, et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002;8:522-6
15. Ross MJ, Bruggeman LA, Wilson PD, Klotman PE. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J Am Soc Nephrol 2001;12:2645-51
16. Alpers CE. Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy. Kidney Int 2003;63:385-96
17. Kimmel PL, Phillips tm, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:702-6
18. Nochy D, Glotz D, Dosquet P, et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant 1993;8:11-9
19. Beaufils H, Jouanneau C, Katlama C, et al. HIV-associated IgA nephropathy: a post-mortem study. Nephrol Dial Transplant 1995;10:35-8
20. Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathological study of 14 cases. Kidney Int 2005;67:1381-90
21. Wali RK, Drachenberg CI, Papadimitriou JC, et al. HIV-1-associated nephropathy and response to highly active antiretroviral therapy. Lancet 1998;352:783-4
22. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006;21:2809-13
23. Ross MJ, Klotman PE. Recent progress in HIV-aasociated nephropathy. J Am Soc Nephrol 2002;13:2997-3004
24. Becker S, Fusco G, Fusco J, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004;39(Suppl 5):S267-75
25. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently. J Acquir Immune Defic Syndr 2004;37(4):1489-95
26. Guo X, Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleveland Clin J Med 2002;69:289-97
27. Krishnan M, Nair R, Haas M, Atta MG, Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis 2000;36(5):1075-8
28. Angel-Moreno-Maroto A, Suarez-Castellano L, Hernandez-Cabrera M, Perez-Arellano JL. Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. J Infect 2006;52:e39-40
29. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004;44(5):e81-4
30. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85
31. Duong M, Sgro C, Grappin M, et al. Renal failure after treatment with ritonavir. Lancet 1996;348:693-4
32. Stricker RB, Man KM, Bouvier DB, et al. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection. Lancet 1997;349:1745-6
33. Witzke O, Plentz A, Schafers RF, et al. Side-effects of ritonavir and its combination with saquinavir with special regard to renal function. AIDS 1997;116:836-8
34. Chugh S, Bird R, Alexander EA. Ritonavir and renal failure. N Engl J Med 1997;336:138
35. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 Recommendations of the International AIDS Society-USA Panel. JAMA 2006;296(7):827-43
36. United States Department of Health and Human Services. Updated Adult and Adolescent Treatment Guidelines, 29 January 2008. Available from: http://aidsinfo.nih.gov [Last accessed 1 April 2008]
37. European AIDS Clinical Society (EACS). Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe. Version 2, December 2007. Available from: www.eacs.eu/guide/index.htm [Last accessed 1 April 2008]
38. British HIV Association. Treatment of HIV-infected adults with antiretroviral therapy (2006). Available from: www.bhiva.org/ cms1191541.asp [Last accessed 1 April 2008]
39. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med 1997;336:138-40
40. Dieleman JP, Sturkenboom MC, Jambroes M, et al. Risk factors for urological symptoms in a cohort of users of the protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002;162:1493-501
41. Daugas E, Rougier J-P, Hill G. HAART-related nephropathies is HIV-infected patients. Kidney Int 2005;67:393-403
42. Casado JL, Moreno A, Sabido R, et al. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clin Trials 2000;1:13-9
43. Young B, Fischl MA, Wilson HM, et al. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naïve HIV-infected adults. J Acquir Immune Defic Syndr 2002;31(5):478-82
44. Arnaiz JA, Mallolas J, Podzamcer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003;17:831-40
45. Voigt E, Wickesberg A, Wasmuth JC, et al. First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Med 2002;3:277-82
46. Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med 1999;340:392-3
47. Dieleman JP, Van Rossum AM, Stricker BC, et al. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J Acquir Immune Defic Syndr 2003;32:135-42
48. Gagnon RF, Tecimer SN, Watters AK, et al. The natural history of leukocyturia associated with indinavir treatment in HIV + individuals. Am J Nephrol 2000;20(6):448-54
49. Sarcletti M, Petter A, Romani N, et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 2000;54:261-70
50. Cattelan AM, Trevenzoli M, Naso A, et al. Severe hypertension and renal atrophy associated with indinavir. Clin Infect Dis 2000;30:619-21
51. Van Rossum AM, Dieleman JP, Fraau PL, et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. AIDS 2001;15:1745-7
52. Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis 2001;38:e23
53. Green ST, McKendrick MW, Schmid ML, et al. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS 1998;9:555-8
54. Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol 2002;167:1384-5
55. Wirth GJ, Teuscher J, Graf JD, Iselin CE. Efavirenz-induced nephrolithiasis. Urol Res 2006;34:288-9
56. Izzedine H, Valantin MA, Daudon M, et al. Efavirenz urolithiasis. AIDS 2007;21(14):1992
57. Thanh D-L, Garrec A, Thomas L, et al. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS 2004;18(4):705-6
58. Chang HR, Pella PM. Atazanavir urolithiasis. N Engl J Med 2006;355(20):2158-9
59. Pacanowski J, Poirier J-M, Petit I, et al. Atazanavir urinary stones in an HIV-infected patient. AIDS 2006;20:2131-2
60. Anderson PL, Lichtenstein KA, Gerig NE, et al. Atazanavir-containing renal calculi in an HIV-infected patient. AIDS 2007;21(8):1060-2
61. Couzigo C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007;45:e105-8
62. Crowther MA, Callaghan W, Hodsman AB, Mackie ID. Dideoxyinosine-associated nephrotoxicity. AIDS 1993;7:131-2
63. Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy. AIDS 2005;19(8):844-5
64. Morris AAM, Baudouin SV, Snow MH. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS 2001;15(1):140-1
65. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med 2006;52:296-7
66. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med 1997;126:257-63
67. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999;282:2305-12
68. Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999;29:948-9
69. Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001;15:1695-700
70. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized double-blind study. AIDS 2002;16:1257-63
71. Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003;139:313-20
72. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. A 3-year randomized trial. JAMA 2004;292(2):191-201
73. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1 infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005;20:743-6
74. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-60
75. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-3
76. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002;324:342-4
77. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-3
78. Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003;37:e41-3
79. Lee JC, Marosok RD. Acute tubular necrosis in a patient receiving tenofovir. AIDS 2003;17:2543-5
80. Creput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003;17:935-7
81. Barrios A, Garcia-Benyas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004;18(6):960-3
82. Saumoy M, Vidal F, Peraire J, et al. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 2004;18:1741-2
83. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity:Fanconi syndrome and renal failure. Am J Med 2004;117:282-4
84. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy. Report of 7 cases. J Acquir Immune Defic Syndr 2004;35(3):269-73
85. Gaspar G, Monereo A, Garcia-Reyne A, De Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS 2004;18(2):351-2
86. Harris M, Yip B, Zalunardo N, et al. Increases in creatinine during therapy with tenofovir DF. Antivir Ther 2003;8(Suppl):S376
87. Harris M, Zalunardo N, Bonner S, et al. Use of estimated glomerular filtration rate (GFR) to predict renal toxicity in patients receiving tenofovir DF (TDF) [abstract 750]. 11th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2004; San Francisco, USA
88. Harris M, Joy R, Zalunardo N, et al. Predictors of creatinine (Cr) increase and drug discontinuation in a province-wide cohort of patients receiving tenofovir DF (TDF). Antivir Ther 2006;11:L12-3
89. Becker S, Balu R, Fusco J. Beyond serum creatinine: identification of renal insufficiency using glomerular filtration: implications for clinical research and care [abstract 819]. 12th Conference on Retroviruses and Opportunistic Infections; 22-25 February 2005; Boston, USA
90. Antoniou T, Raboud J, Chirhin S, et al. Incidence and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005;6:284-90
91. Young B, Buchacz K, Baker RK, et al. Ranal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care 2007;6(3):178-87
92. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006;42:283-90
93. Nelson M, Cooper D, Schooley R, et al. The safety of tenofovir DF for the treatment of HIV infection: the first 4 years. AIDS 2007;10:1273-81
94. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-8
95. Winston A, Amin J, Mallon P, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006;7(2):105-11
96. Moreno S, Domingo P, Palacios R, et al. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. J Acquir Immune Defic Syndr 2006;42(3):385-7
97. Julg BD, Bogner JR, Crispin A, Goebel FD. Progression of renal impairment under therapy with tenofovir. AIDS 2005;19(12):1332-3
98. Thompson M, Haubrich R, Margolis D, et al. Differences in calculated glomerular filtration rates in efavirenz- or tenofovir-treated adults in ESS40006 [abstract 777]. 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, USA
99. Guest J, Rimpland D, Patterson B, Desilva K. Tenofovir-induced nephrotoxicity in the first year of therapy [abstract 778]. 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, USA
100. Hanson D, Voetsch A, McNaghten A, Sullivan P. Renal impairment associated with the use of tenofovir [abstract 779]. 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, CO, USA
101. Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003;36:1082-5
102. Cote HCF, Magil AB, Harris M, et al. Exploring mitochondrial toxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on HAART. Antivir Ther 2006;11:79-86
103. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 2007;11:1431-9
104. Rollot F, Nasal E-M, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003;37:e174-6
105. Callens S, De Roo A, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect 2003;47:262-3
106. Louie S, Lam J, Neely M, Beringer P. Multidrug resistance protein 2 (MRP2) inhibition by ritonavir increases TFV-associated cytotoxicity [abstract 23]. 6th International Workshop on Clinical Pharmacology of HIV Infection; 2005; Quebec City, Canada
107. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50:3297-304
108. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008;83:265-72
109. Molina J-M, Andrade-Villanueva J, Echevarria E, et al. Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritoanvir, each in combination with tenofovir and emtricitabine in ARV-naïve HIV-1-infected subjects: the CASTLE Study, 48-week results [abstract 37]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, USA
110. Smith KL, Fine D, Patel P, et al. Efficacy and safety of abacavir/ lamivudine compared to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT Study [abstract 774]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA, USA
111. Gathe J, da Silva BA, Loutfy M, et al. Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ ritonavir tablets once daily vs twice daily, co-administered with tenofovir DF + emtricitabine in ARV-naïve HIV-1-infected subjects [abstract 775]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, USA
112. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1 infected patients. AIDS 1998;12(15):F167-73
113. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 2003;37(Suppl 2):S85-90
114. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005;19:1375-83
115. Cattelan AM, Trevenzoli M, Sasset L, et al. Indinavir and systemic hypertension. AIDS 2001;15(6):805-7
116. Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005;19(9):953-60
117. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999;100:700-5
118. Friis-Moller N, Weber R, Reisa P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-93
119. Friis-Moller N, Sabin CA, Webee R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003
120. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35
121. Podzamcer D, Ferrer E, Sanchez P, et al. less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007;44(2):139-47
122. Van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naïve patients infected with HIV-1. PLoS Med 2004;1(1):e19
123. Haubrich R, Riddler S, Dirienzo G, et al. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection [abstract 38]. 14th Conference on Retroviruses and Opportunistic Infections; 25 - 28 February 2007; Los Angeles, CA, USA
124. Viread® product information. Gilead Sciences, Inc. Foster City, USA; 2007
125. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 AIDS 2002;16:569-77
126. Schmidt GA, Hoehns JD, Purcell JL, et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 2007;20:411-6
127. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25:2822-35
128. Palacios R, Santos J, Gonzalez M, et al. Efficacy and safety of atorvastain in the treatment of hypercholesterolemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002;30:536-7
129. Mallon PW, Miller J, Kovacic JC, et al. Effect of pravastatin on body copmposition and markers of cardiovascular disease in HIV-infected men - a randomized, placebo-controlled study. AIDS 2006;20(7):1003-10
130. Bonnet F, Aurillac-Lavignolle V, Breilh D, et al. Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin Trials 2007;8(1):53-60
131. Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005;19:1103-5
132. Back D. Drug-drug interactions that matter. Top HIV Med 2006;14(2):88-92
133. Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (tmC114) and the lipid-lowering agent pravastatin [abstract 54]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 16 - 18 April 2007; Budapest, Hungary
134. Van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007;12(7):1127-32
135. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008;47(5):570-8
136. Pham PA, Lee L, Fuchs E, et al. Pharmacokinetic interaction between tipranavir/ritonavir and rosuvastatin [abstract 767]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, USA
137. Liverpool HIV Pharmacology Group. Drug interactions chart. Available from: http://www.hiv-druginteractions.org [Last accessed 1 April 2008]
138. Fine D. Renal disease and toxicities: issues for HIV care providers. Top HIV Med December 2006/January 2007;14(5):164-9
139. Bohanjen PR, Johnson MD, Szczech LA, et al. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother 2002;46:2387-92
140. Intelence™ full prescribing information. Tibotec, Inc. Raritan, USA; 2008
141. Aptivus® product information. Boehringer Ingelheim International GmbH; 2007
142. Prezista™ prescribing information. Tibotec, Inc. Raritan, USA; 2008
143. Fuzeon product information. Roche Laboratories, Inc., Nutley, USA and Trimeris, Inc., Morrisville, USA; 2007
144. Tebas P, Bellos N, Lucasti C, et al. Enfuvirtide does not require dose adjustment in patients with chronic kidney disease: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. J Acquir Immune Defic Syndr 2008;47(3):342-5
145. Isentress prescribing information. Merck & Co. Inc., Whitehouse Station, NJ; 2008
146. Selzentry™ prescribing information. Pfizer, Inc., New York, USA; 2007
147. Cihlar T, Birkus B, Greenwalt DE, Hitchcock MJM. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriprase inhibitors. Antiviral Res 2002;54:37-45
148. British Columbia Centre for Excellence in HIV/AIDS. Therapeutic guidelines: antiretroviral therapy for HIV-1 infected adults. October 2006. Available from: www.cfenet.ubc.ca [Last accessed 1 April 2008]
149. Szczech LA, Edwards LJ, Sanders LL, et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 2002;57:336-41
150. Franceschini N, Napravnik S, Eron JJ Jr, et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005;67:1526-31
151. Izzedine H, Brocheriou I, Martinez V, Deray G. Immune reconstitution inflammatory syndrome and acute granulomatous interstitial nephritis. AIDS 2007;21:534-5
152. Basu D, Williams FM, Ahn CW, Reveille JD. Changing spectrum of the diffuse infiltrative lymphocytosis syndrome. Arthritis Rheum 2006;55:466-72